When Innovation Leaves the Academic Medical Center, Can Community Hospitals Afford to Follow?
By Nicole Coustier and Melissa Muller
On Friday, July 31, CMS released the FY 2027 Inpatient Prospective Payment System (IPPS) final rule, establishing how Medicare will pay acute-care hospitals beginning October 1. For MedTech innovators, attention typically turns first to new technology add-on payments, changes in MS-DRG assignments and relative weights, and other provisions that directly affect reimbursement.
But one discussion in this year’s rule raises a broader commercialization question. Commenters argued that CMS’s annual recalibration of MS-DRG weights can disadvantage rural hospitals by reducing payment for the lower-acuity cases they disproportionately treat, further limiting their ability to invest in the specialists, infrastructure, and technologies needed to retain more complex patients.
This matters because innovation spreads through people, but it takes root through institutions. Academic medical centers may be where clinicians first learn to use new technologies, but payment and institutional capacity help determine whether those technologies can follow them into community practice.
MedTech companies often build their early commercialization strategy around major academic medical centers, and for good reason.
These institutions have experienced investigators, specialized infrastructure, research support, complex patient populations, and clinicians willing to adopt technologies before they become routine. They generate the evidence, reference sites, publications, and key opinion leaders that can establish a new technology’s credibility.
But innovation does not remain inside academic medicine. Fellows and other trainees learn to use new technologies at major institutions and then move into community and regional hospitals. They bring with them clinical experience, expectations about the standard of care, and familiarity with products that may not yet be widely adopted.
These physicians can become an important but underappreciated channel for technology dissemination. They may arrive at a community hospital prepared to champion a technology they used during training. The problem is that clinical readiness does not guarantee institutional capacity to adopt it.
The FY 2027 IPPS final rule highlights why.
The DRG recalibration problem
CMS recalibrates MS-DRG relative weights annually to reflect changes in the resources associated with different types of inpatient cases. Because recalibration is budget neutral, increases in some DRG weights are offset by reductions elsewhere.
Commenters on the FY 2027 rule argued that this process can systematically disadvantage rural hospitals. These hospitals tend to treat a greater proportion of lower-acuity cases, where relative weights may decline, while treating fewer of the complex cases whose weights increase.
The result, according to commenters, is a reinforcing cycle: Lower-acuity case mix leads to lower payment. Lower payment limits investment in specialists, infrastructure, and technology. Without those investments, the hospital remains unable to retain more complex patients. Those patients continue to be transferred to tertiary centers, and the hospital’s case-mix index remains low.
CMS did not adopt the commenters’ proposed case-mix adjustment. The agency maintained that its recalibration methodology appropriately reflects relative resource use and fulfills statutory budget-neutrality requirements.
But the issue has implications beyond hospital finance. It affects how innovation spreads.
Clinicians may disseminate innovation but payment determines whether it takes root
The conventional MedTech adoption model assumes a fairly linear progression:
Establish use at academic centers.
Generate evidence and physician advocacy.
Expand into regional and community markets.
That model overlooks an important link between the first and third steps: physician movement.
A fellow trained at a major academic center may become a community hospital’s strongest internal advocate for a new technology. This physician already understands the procedure, patient selection, workflow, and clinical value. From the manufacturer’s perspective, much of the usual adoption barrier has already been removed.
Yet the hospital may still be unable to say yes.
A community hospital with declining or persistently low DRG payments may have limited ability to absorb:
A device cost not adequately recognized in the DRG;
Capital equipment and service contracts;
Staff training and implementation expenses;
Additional operating-room or procedural time;
Uncertain utilization during the ramp-up period; or
The financial risk of retaining more complex patients.
This creates a paradox: the clinician most prepared to disseminate an innovation may practice at an institution least equipped to finance its adoption.
The paradox is also institutional
Financial capacity explains part of the gap, but not all of it. Even where the money exists, someone inside the hospital has to ask for it, and that request travels a specific path: a physician request, a value analysis review, a capital request, a budget cycle, and a service-line leader who has to defend the number afterward. Each of those steps has an owner. A newly arrived physician rarely knows who any of them are. Nor is that review merely bureaucratic. Value analysis exists as a patient safety function as much as a financial one, and a committee that declines a request is sometimes doing its job precisely.
That is the second half of the paradox. The clinician best prepared to introduce a technology is often the person with the least institutional standing to get it approved. They have no volume history at that hospital to forecast against, no track record with the value analysis committee, no established relationship with finance or supply chain, and no accumulated credibility to spend on a request that will be scrutinized precisely because it is unfamiliar.
A financial model built on an academic center’s volumes, payer mix, and staffing is unlikely to survive a community hospital’s finance review. What the champion needs is an analysis of incremental contribution margin at the local institution, together with the downstream and avoided-transfer effects the service line can credibly claim. None of this contradicts the payment argument; it compounds it. Weak DRG payment lowers the ceiling on what a community hospital can absorb, while an unprepared internal case means the request may never reach that ceiling in the first place.
This changes the commercialization question
For innovators, the question should not be only:
“Which academic centers will adopt our technology first?”
It should also be:
“What must be true for our physician champions trained at those centers to bring our technology into their next institutions?”
That requires a commercialization strategy designed for diffusion, not merely early adoption.
A technology that succeeds at a nationally recognized academic center may depend on institutional resources that cannot be replicated in a community setting. If the economics only work at hospitals with high case-mix indexes, large procedure volumes, dedicated innovation funds, or the ability to subsidize early use, the product may remain concentrated in those centers.
The academic-center strategy is still essential. But companies should use those sites as both evidence-generation centers and launch points for a broader clinical network.
Building a dissemination strategy
MedTech companies can prepare for this second stage earlier than they typically do.
Track the clinician network. Fellows and trainees who have used the technology may become future champions. Companies should understand where they go, what types of institutions employ them, and which barriers they encounter when attempting to introduce the technology.
Develop community-specific economics. A value proposition created for a large academic medical center may not translate to a 150-bed regional hospital. The community case should address patient retention, avoided transfers, downstream service-line revenue, staffing requirements, procedural efficiency, and the realistic local Medicare case mix.
Identify the adoption threshold. Determine the minimum volume, payment, and infrastructure required for the technology to be financially sustainable. If those conditions are unrealistic outside tertiary centers, the company may need to reconsider pricing, contracting, equipment placement, or the implementation model. That threshold is clinical as well as financial. For many procedures, outcomes track institutional and operator volume, which means broader diffusion is not automatically safer diffusion. If a hospital cannot reach the case volume required to build and hold competence, the technology should not go there yet, and the company should know that before it places a representative in the account.
Generate transferable evidence. Evidence from expert operators at academic centers establishes efficacy, but community hospitals also need evidence that the technology can be implemented safely and efficiently in less specialized environments.
Treat reimbursement as a dissemination mechanism. Coding and payment strategy should anticipate where the technology is ultimately intended to be used, not only where the first cases will occur. A DRG that appears adequate at a large teaching hospital may not create a viable adoption pathway for the broader market.
Equip the champion to survive value analysis. Clinical evidence is not an internal business case. The champion needs a defensible financial summary at local volumes and payer mix, a clear view of which internal stakeholders must be aligned before the request is submitted, and honest answers to the objections finance and supply chain will raise. A company cannot approve the purchase. It can make sure the person who has to ask for it is not asking alone.
The Innovator’s Role
Academic centers train the physicians who carry new practices into communities. Those clinicians can introduce technologies, build new service lines, and reduce the need for patients to travel to distant tertiary centers.
That matters clinically, not only logistically. Transfer carries its own risk: delay in time-sensitive conditions, information loss at handoff, fragmented follow-up, and distance that separates patients from the family support that sustains recovery. When a community hospital cannot adopt, the patient is not merely inconvenienced. The patient is moved.
But that dissemination pathway depends on whether community hospitals have enough financial capacity to act on the expertise arriving at their doors.
The rural-hospital concerns raised in the FY 2027 IPPS final rule are therefore not simply a debate about DRG weights. They raise a larger question for MedTech innovators:
If payment policy weakens the hospitals that represent the next stage of adoption, how broadly can innovation actually spread?
A successful market-access strategy must account for both sides of the equation: cultivating innovation at leading academic centers and creating an economic pathway that allows that innovation to follow clinicians into the communities they ultimately serve.
Do you have U.S. commercialization questions?
Whether it's how the multiple payer landscape works in the U.S., how to validate device or procedure coding, timelines associate with product uptake - we're happy to answer them.
🔗Schedule an introductory call https://calendly.com/nicolecoustier
